Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aldesleukin and CD25-depleted lymphocytes in metastatic melanoma
NCT00138229Phase 2Terminated
- Sponsor
- National Institutes of Health
- Start
- Jul 2005
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of therapeutic autologous lymphocytes in melanoma, sponsored by National Institutes of Health. Started Jul 2005; status: terminated.
02
Drugs
therapeutic autologous lymphocytes
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00138229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00138229.